Dolsten Mikael 4
4 · ROCKET PHARMACEUTICALS, INC. · Filed Apr 24, 2025
Insider Transaction Report
Form 4
Dolsten Mikael
Director
Transactions
- Other
Common Stock
2025-03-05+14,220→ 14,220 total
Footnotes (2)
- [F1]Represent restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will become fully vested on December 31, 2025.
- [F2]Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, effective March 3, 2025, for services related to the Company's research and development activities. As part of the compensation for services rendered, the Reporting Person received $125,000 of RSUs valued based on the closing price of the Company's common stock on March 3, 2025, which will cliff vest on December 31, 2025.